0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

SODIUM THIOSULFATE AND THE ELIMINATION OF ARSENIC

SAMUEL AYRES Jr., M.D.; NELSON PAUL ANDERSON, M.D.
JAMA. 1938;110(12):886-887. doi:10.1001/jama.1938.02790120028007.
Text Size: A A A
Published online

The administration of sodium thiosulfate for the treatment of arsenical dermatitis has been an accepted procedure among dermatologists ever since it was first introduced by Ravaut,1 in 1920. In this country McBride and Dennie2 confirmed the value of the treatment, and since then numerous clinicians have attested its value in shortening the duration and lessening the severity of arsenical eruptions, especially postarsphenamine dermatitis. A number of investigators3 have shown that the administration of sodium thiosulfate orally or intravenously causes a prompt and pronounced increase in the elimination of arsenic, followed in the course of several weeks by a gradual diminution in the output of urinary arsenic, to the point where only traces or none at all can be detected, although it must be admitted that carefully compiled statistical studies have not been numerous. Some conflicting reports, however, have appeared, notably those of Young4 and of Mattice

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();